Works by Byoung Chul Cho

Results: 129
    1

    A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study.

    Published in:
    Clinical Lung Cancer, 2024, v. 25, n. 3, p. 266, doi. 10.1016/j.cllc.2024.03.003
    By:
    • Garon, Edward B.;
    • Byoung Chul Cho;
    • Luft, Alexander;
    • Alatorre-Alexander, Jorge;
    • Geater, Sarayut Lucien;
    • Dmytro Trukhin;
    • Sang-We Kim;
    • Ursol, Grygorii;
    • Hussein, Maen;
    • Louise Lim, Farah;
    • Cheng-Ta Yang;
    • Araujo, Luiz Henrique;
    • Haruhiro Saito;
    • Reinmuth, Niels;
    • Kohlmann, Milena;
    • Lowery, Caitlin;
    • Mann, Helen;
    • Peters, Solange;
    • Mok, Tony S.;
    • Johnson, Melissa L.
    Publication type:
    Article
    2
    3

    Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD).

    Published in:
    Clinical Lung Cancer, 2021, v. 22, n. 6, p. 601, doi. 10.1016/j.cllc.2021.06.006
    By:
    • Yu, Helena A.;
    • Goldberg, Sarah B.;
    • Le, Xiuning;
    • Piotrowska, Zofia;
    • Goldman, Jonathan W.;
    • De Langen, Adrianus J.;
    • Okamoto, Isamu;
    • Cho, Byoung Chul;
    • Smith, Paul;
    • Mensi, Ilhem;
    • Ambrose, Helen;
    • Kraljevic, Silvija;
    • Maidment, Julie;
    • Chmielecki, Juliann;
    • Li-Sucholeiki, Xiaocheng;
    • Doughton, Gail;
    • Patel, Gargi;
    • Jewsbury, Phil;
    • Szekeres, Phil;
    • Riess, Jonathan W.
    Publication type:
    Article
    4

    Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer (MYSTIC).

    Published in:
    Clinical Lung Cancer, 2021, v. 22, n. 4, p. 301, doi. 10.1016/j.cllc.2021.02.010
    By:
    • Garon, Edward B.;
    • Cho, Byoung Chul;
    • Reinmuth, Niels;
    • Lee, Ki Hyeong;
    • Luft, Alexander;
    • Ahn, Myung-Ju;
    • Robinet, Gilles;
    • Le Moulec, Sylvestre;
    • Natale, Ronald;
    • Schneider, Jeffrey;
    • Shepherd, Frances A.;
    • Garassino, Marina Chiara;
    • Geater, Sarayut Lucien;
    • Szekely, Zsolt Papai;
    • Van Ngoc, Tran;
    • Liu, Feng;
    • Scheuring, Urban;
    • Patel, Nikunj;
    • Peters, Solange;
    • Rizvi, Naiyer A.
    Publication type:
    Article
    5
    6
    7
    8
    9
    10

    Pharmacokinetics (PK) of Tiragolumab in First‐in‐Human Study in Patients with Mixed Solid Tumors (GO30103).

    Published in:
    Journal of Clinical Pharmacology, 2024, v. 64, n. 5, p. 544, doi. 10.1002/jcph.2397
    By:
    • Garralda, Elena;
    • Oh, Do Youn;
    • Italiano, Antoine;
    • Bedard, Philippe L.;
    • Delord, Jean‐Pierre;
    • Calvo, Emiliano;
    • LoRusso, Patricia;
    • Wainberg, Zev;
    • Cervantes, Andres;
    • Rodriguez‐Vida, Alejo;
    • Shemesh, Colby S.;
    • Sane, Rucha;
    • Mendus, Diana;
    • Ding, Hao;
    • Hendricks, Robert;
    • Meng, Ray;
    • Cho, Byoung Chul;
    • Kim, Tae Won;
    • Wu, Benjamin
    Publication type:
    Article
    11

    Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors.

    Published in:
    Targeted Oncology, 2023, v. 18, n. 1, p. 105, doi. 10.1007/s11523-022-00931-9
    By:
    • Kollmannsberger, Christian;
    • Hurwitz, Herbert;
    • Bazhenova, Lyudmila;
    • Cho, Byoung Chul;
    • Hong, David;
    • Park, Keunchil;
    • Reckamp, Karen L.;
    • Sharma, Sunil;
    • Der-Torossian, Hirak;
    • Christensen, James G.;
    • Faltaos, Demiana;
    • Potvin, Diane;
    • Tassell, Vanessa;
    • Chao, Richard;
    • Shapiro, Geoffrey I.
    Publication type:
    Article
    12
    13
    14
    15
    16
    17
    18
    19
    20

    Exploring aryl hydrocarbon receptor expression and distribution in the tumor microenvironment, with a focus on immune cells, in various solid cancer types.

    Published in:
    Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2024.1330228
    By:
    • Dong Kwon Kim;
    • Chai Young Lee;
    • Yu Jin Han;
    • So Young Park;
    • Heekyung Han;
    • KwangminNa;
    • Mi Hyun Kim;
    • Seung Min Yang;
    • Sujeong Baek;
    • Youngtaek Kim;
    • Joon Yeon Hwang;
    • Seul Lee;
    • Seong-san Kang;
    • MinHee Hong;
    • Sun Min Lim;
    • Jii BumLee;
    • JaeHwan Kim;
    • Byoung Chul Cho;
    • Kyoung-Ho Pyo
    Publication type:
    Article
    21
    22
    23
    24
    25
    26
    27
    28

    Updated overall survival and ctDNA analysis in patients with EGFR T790M-positive advanced non-small cell lung cancer treated with lazertinib in the phase 1/2 LASER201 study.

    Published in:
    BMC Medicine, 2024, v. 22, n. 1, p. 1, doi. 10.1186/s12916-024-03620-8
    By:
    • Han, Ji-Youn;
    • Ahn, Myung-Ju;
    • Lee, Ki Hyeong;
    • Lee, Yun-Gyoo;
    • Kim, Dong-Wan;
    • Min, Young Joo;
    • Kim, Sang-We;
    • Cho, Eun Kyung;
    • Kim, Joo-Hang;
    • Lee, Gyeong-Won;
    • Lee, Sung Sook;
    • Lee, Na Mi;
    • Jang, Hyun Woo;
    • Han, Heewon;
    • Park, Hyejoo;
    • Lee, Jieon;
    • Cho, Byoung Chul
    Publication type:
    Article
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49
    50